Tirzepatide

GLP-1 / MetabolicResearch Use Only

Also known as: Mounjaro (brand), Zepbound (brand), GIP/GLP-1 dual agonist

Tirzepatide is a dual GIP and GLP-1 receptor agonist commonly referenced in metabolic research literature. Studies describe its combined action on two incretin pathways relevant to glucose regulation and appetite. It is frequently discussed for its once-weekly dosing profile.

Typical range (research)

Research literature commonly references escalating weekly amounts in the ~2.5–15 mg/week range

Half-life

~5 days

Route

Subcutaneous (research)

Common use

Metabolic and weight-management research

Common vial sizes

5 mg · 10 mg · 15 mg · 30 mg

Storage

Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.

Stacking notes

Discussed in research as a single-molecule dual agonist; combining with other incretin agents is generally not referenced and would compound gastrointestinal effects.

Reported side effects

NauseaReduced appetiteDiarrheaConstipation

Regulatory note: Prescription drug in Canada and the US; approved for type 2 diabetes and chronic weight management under brand names. Research-grade material is not for human use.

Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.